Two Sigma Investments’s Nabriva Therapeutics plc Ordinary Shares Ireland NBRV Stock Holding History

Two Sigma Investments’s Portfolio NBRV Stock Details NBRV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q1	–	Sell	-685	Closed	-$226K	–	4099
2019 Q4	$226K	Buy	685 +279	+69%	+$128K	﹤0.01%	3361
2019 Q3	$203K	Buy	+406	New	+$229K	﹤0.01%	3188
2019 Q2	–	Sell	-502	Closed	-$306K	–	3823
2019 Q1	$306K	Buy	502 +271	+117%	+$148K	﹤0.01%	2587
2018 Q4	$84K	Sell	231 -261	-53%	-$140K	﹤0.01%	2830
2018 Q3	$332K	Buy	+492	New	+$349K	﹤0.01%	2708

Other funds holding NBRV

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

Frazier Management Seattle, Washington $1.12M AUM 151.58% 1-Year Est. Return

ACM

Aisling Capital Management New York $476M AUM 128.63% 1-Year Est. Return

Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return

FNC

First National Corp Rockland, Massachusetts $527M AUM 12.33% 1-Year Est. Return

RSCM

Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

VFA

Values First Advisors Gray, Tennessee $219M AUM 33.32% 1-Year Est. Return

Sabby Management Miami Beach, Florida $45.1M AUM 74.25% 1-Year Est. Return

Two Sigma Investments's NBRV Position: Q1 2020 in Review

Two Sigma Investments sold out of Nabriva Therapeutics plc Ordinary Shares Ireland (NBRV) in Q1 2020, closing a stake of 685 shares — an estimated $226K sold.

Two Sigma Investments first reported a position in NBRV in Q3 2018 and held it in 5 quarters. The position peaked at $332K in Q3 2018. 50 funds tracked by Wall St. Rank hold NBRV as of Q1 2020.

Two Sigma Investments reported no remaining Nabriva Therapeutics plc Ordinary Shares Ireland position as of Q1 2020 after selling out during the quarter.
Two Sigma Investments sold 685 Nabriva Therapeutics plc Ordinary Shares Ireland shares in Q1 2020, an estimated $226K.
Two Sigma Investments first reported a position in Nabriva Therapeutics plc Ordinary Shares Ireland in Q3 2018 and held it in 5 quarters.
Two Sigma Investments's Nabriva Therapeutics plc Ordinary Shares Ireland position peaked at $332K in Q3 2018.
50 funds tracked by Wall St. Rank held Nabriva Therapeutics plc Ordinary Shares Ireland as of Q1 2020.

Based on Two Sigma Investments's 13F filing for Q1 2020, filed 15 May 2020.